No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer
Abstract Background Studies over the past 10 years strongly support an association between skeletal muscle mass (SMM) depletion and outcome in metastatic colorectal cancer (mCRC). Factors influencing SMM changes over time are, however, poorly studied. We analyzed the impact of SMM on overall surviva...
Main Authors: | Sami Antoun, Mohamed Amine Bayar, Valérie Dyevre, Emilie Lanoy, Cristina Smolenschi, Michel Ducreux |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-6086-2 |
Similar Items
-
Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience
by: Elisabetta Fenocchio, et al.
Published: (2019-03-01) -
Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01) -
Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients
by: Sophie Kurk, et al.
Published: (2019-08-01) -
Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer: single center experience
by: Ocvirk Janja, et al.
Published: (2016-06-01) -
Pharmacoeconomic-guided choice of systemic chemotherapy in metastatic colorectal cancer patients
by: M. Yu. Fedyanin, et al.
Published: (2017-09-01)